← Eichor
Condition: Hormone Receptor Positive Breast Adenocarcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Hormone Receptor Positive Breast Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
Phase N/A · 1 location(s) · Mayo Clinic · NCT06388122AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Phase 1 · 3 location(s) · Avacta Life Sciences Ltd · NCT07454642A Study of Revaree Plus in People With Breast Cancer
Phase 4 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07042581BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 · 63 location(s) · BeOne Medicines · NCT06120283Mobile Health for Adherence in Breast Cancer Patients
NA · 506 location(s) · ECOG-ACRIN Cancer Research Group · NCT06112613Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Recep
Phase 2 · 9 location(s) · Jonsson Comprehensive Cancer Center · NCT04553770Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Phase 1 · 12 location(s) · Aktis Oncology, Inc. · NCT07020117Neoadjuvant Breast Cancer Time Restricted Eating
NA · 1 location(s) · Thomas Jefferson University · NCT053276085-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
Phase 2 · 1 location(s) · Mayo Clinic · NCT07044310Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast
Phase 2 · 2 location(s) · University of Washington · NCT06179303Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-S
NA · 4 location(s) · Emory University · NCT06534125Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NA · 39 location(s) · Natera, Inc. · NCT07214532Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Br
Phase 2 · 72 location(s) · MedSIR · NCT06486883A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Recept
Phase 2 · 1 location(s) · University of Washington · NCT07112053The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients
Phase N/A · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT07341503Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast
EARLY_Phase 1 · 4 location(s) · Emory University · NCT05464810Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide,
Phase 3 · 544 location(s) · National Cancer Institute (NCI) · NCT06058377Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormon
Phase N/A · 24 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06805812ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
Phase 2 · 1 location(s) · Laura Huppert, MD, BA · NCT06224673Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally A
Phase 2 · 1 location(s) · Mayo Clinic · NCT07460752Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
Phase 2 · 6 location(s) · City of Hope Medical Center · NCT04305834Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for H
Phase 1 · 2 location(s) · National Cancer Institute (NCI) · NCT07137416
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.